natgillin/translations-raw huggingface dataset:
When you wish your period to begin during the second blister, stop taking the white active tablets and start taking the yellow placebo tablets.
prestanite uzimati bijele tablete s djelatnim tvarima i počnite uzimati žute tablete placeba.
Uncommon (may affect up to 1 in 100 people): • increased appetite; fluid retention (oedema)
Vrlo često (mogu se javiti u više od 1 na 10 osoba): • akne
Day 18-24 of white active tablet intake (see picture and schedule) There is a particularly high risk of becoming pregnant if you miss white active tablets close to the yellow placebo tablet interval.
Postoji osobito visoki rizik od trudnoće ako propustite bijele tablete s djelatnim tvarima oko razdoblja uzimanja žutih tableta placeba.
The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table).
Rizik od arterijskih tromboembolijskih komplikacija ili cerebrovaskularnog incidenta u korisnica
Tel: + 421 2 58282010 dpoc_czechslovak@merck.com
Τηλ: + 30 210 98 97 300 dpoc_greece@merck.com
Interactions
Linearnost
Obesity (body mass index over 30 kg/m²)
Pretilost (indeks tjelesne mase veći od
Available pharmacokinetic
5.2 Farmakokinetička svojstva
• swelling and slight blue discolouration of an extremity; • severe pain in your stomach (acute abdomen).
• jaka bol u trbuhu (akutni abdomen)
Do not use this medicine in children and adolescents under 13 years of age.
Nemojte koristiti ovaj lijek u djece i adolescenata mlađih od 13 godina.
• past experience with excessive gambling
• prethodnog iskustva pretjeranog kockanja.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i lijekove koje ste nabavili bez recepta.
Aluminium//Aluminium blister.
Aluminij/aluminij blister.
Str. Livezeni nr. 7A Târgu Mureş 540472 Romania
Str. Livezeni nr. 7A Târgu Mureş 540472 Rumunjska
Use within 3 months after first opening of the bottle.
Uporabiti unutar 3 mjeseca od prvog otvaranja boce.
Consequently, the frequency of these adverse events is qualified as "not known"
Posljedično tome, učestalost ovih nuspojava navodi se kao "nepoznata".
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 August 2015
Datum prvog odobrenja: 20. kolovoz 2015.
If you forget to take Aripiprazole Sandoz If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.
Ako ste zaboravili uzeti Aripiprazol Sandoz Ako ste propustili uzeti dozu, uzmite je čim se sjetite, ali nemojte uzeti dvije doze u jednom danu.
OUTER CARTON FOR BOTTLE AND LABEL FOR BOTTLE
VANJSKO PAKIRANJE ZA BOCU I NALJEPNICA ZA BOCU
increase in appetite and feeling weak) or family history of diabetes
povećanog apetita i osjećaja slabosti) ili šećerne bolesti u obiteljskoj povijesti bolesti
Do not take Aripiprazole Sandoz • if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Aripiprazol Sandoz • ako ste alergični na aripiprazol ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6.).
Prolactin levels were evaluated in all trials of all doses of aripiprazole (n=28,242).
Razine prolaktina evaluirane su u svim ispitivanjima svih doza aripiprazola (n = 28,242).
It is especially important to mention the following to your doctor:
Osobito je važno da kažete liječniku ako uzimate sljedeće
Clinical efficacy and safety
Klinička djelotvornost i sigurnost Odrasli
EXP Use within 3 months after first opening.
Uporabiti unutar 3 mjeseca od prvog otvaranja.
The table is based on adverse events reported during clinical trials and/or post-marketing use.
Tablica se temelji na nuspojavama prijavljenima tijekom kliničkih ispitivanja i/ili nakon stavljanja lijeka u promet.
Tablet 100 tablets
100 tableta
If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your carer/relative should tell your doctor if you have ever had a stroke or "mini" stroke.
Ako ste starija osoba i bolujete od demencije (gubitka pamćenja i drugih mentalnih sposobnosti), Vi ili Vaš skrbnik/član obitelji morate obavijestiti liječnika ako ste preboljeli moždani udar ili “mali” moždani udar.
Indigo Carmine (E132) Aluminium lake
Indigo carmine aluminium lake (E132)
Before treatment with Aripiprazole Sandoz, tell your doctor if you suffer from
Prije liječenja lijekom Aripiprazol Sandoz, obavijestite svog liječnika ako bolujete od
See leaflet for further information.
Za dodatne informacije pogledajte uputu.
Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole Cmax by about 41% and AUC by about 51%, suggesting that charcoal may be effective in the treatment of overdose.
Aktivni ugljen (50 g), primijenjen jedan sat nakon aripiprazola, smanjio je Cmax aripiprazola za otprilike 41 %, a AUC za 51 %, što ukazuje na to da bi ugljen mogao biti učinkovit u liječenju predoziranja.
However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6% of the bile concentrations found in the monkeys in the 39-week study and are well below (6%) their limits of in vitro solubility.
Međutim, koncentracije sulfatnih konjugata hidroksi-aripiprazola u ljudskoj žuči pri najvišoj predloženoj dozi od 30 mg dnevno nisu bile veće od 6 % koncentracije u žuči pronađene u majmuna u 39-tjednom ispitivanju i daleko su ispod (6 %) njihovih granica topljivosti in vitro.
The PSUR for the brand leader, Abilify and Abilify Maintena, gathers data from the immediate-realease formulations and the prolonged-release suspension for injection.
Za PSUR za vodeća zaštićena imena, Abilify i Abilify Maintena, prikupljaju se podaci o formulacijama s trenutnim oslobađanjem i suspenziji za injekciju s produljenim oslobađanjem.
Packsizes:
Veličine pakiranja:
Given that dystonia is a well-known side effect of this drug and the large number of reported cases it seems likely that aripiprazole can cause oculogyric crisis.
S obzirom na to da je distonija dobro poznata nuspojava ovog lijeka i da postoji velik broj prijavljenih slučajeva, čini se vjerojatnim da aripiprazol može uzrokovati okulogirnu krizu.
At therapeutic concentrations, aripiprazole and dehydroaripiprazole are greater than 99% bound to serum proteins, binding primarily to albumin.
Pri terapijskim koncentracijama, više od 99 % aripiprazola i dehidro-aripiprazola vezano je za serumske proteine, prvenstveno za albumin.
Consequently, newborn infants should be monitored carefully (see section 4.8).
Posljedično, novorođenčad se mora pažljivo motriti vidjeti dio 4.8).
In addition, cases of stroke or "mini" stroke have been reported.
Osim toga, prijavljeni su slučajevi moždanog udara ili “malog” moždanog udara.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic.
Na temelju rezultata punog raspona standardnih testova genotoksičnosti, smatra se da aripiprazol nije genotoksičan.
Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim poremecajem nepodnošenja galaktoze, nedostatkom Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne bi trebali uzimati ovaj lijek.
Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.
Budući da bolesnici liječeni antipsihoticima često već imaju stečene čimbenike rizika za VTE, prije i tijekom liječenja lijekom aripiprazol moraju se utvrditi svi mogući čimbenici rizika za VTE i poduzeti preventivne mjere.
The European Medicines Agency has deferred the obligation to submit the results of studies with the reference medicinal product containing aripiprazole in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).
Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja sa referentnim lijekom koji sadrži aripiprazol u jednoj ili više podskupina pedijatrijske populacije za liječenje shizofrenije te za liječenje bipolarnog afektivnog poremećaja (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
In this PSUR, there are 15 spontaneous reports of oculogyric crisis (8 serious) in the interval and 223 cumulatively (78 serious) for the oral formulations, comparing to 5 spontaneous reports of oculogyric crisis (3 serious) in the interval and 21 cumulatively (14 serious) for the prolonged-release suspension for injection.
Ovaj PSUR sadrži 15 spontanih prijava okulogirne krize (8 ozbiljnih) iz promatranog razdoblja i 223 kumulativno (78 ozbiljnih) za peroralne formulacije, u odnosu na 5 spontanih prijava okulogirne krize (3 ozbiljne) u promatranom razdoblju i 21 kumulativno (14 ozbiljnih) za suspenziju za injekciju s produljenim oslobađanjem.
It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
Koriste se za liječenje odraslih i adolescenata u dobi od 15 ili više godina koji boluju od bolesti karakterizirane simptomima kao što su da bolesnik čuje, vidi ili osjeća stvari kojih nema, sumnjičavost, pogrešno vjerovanje, nepovezan govor i ponašanje te emocionalna tupost.
How to store Aripiprazole Sandoz tablets Contents of the pack and other information
Kako čuvati Aripiprazol Sandoz Sadržaj pakiranja i druge informacije
Do not use this medicine after the expiry date which is stated on the blister, bottle and carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru, boci i kutiji.
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.
Farmakokinetika aripiprazola i dehidro aripiprazola u pedijatrijskih bolesnika u dobi od 10 do 17 godina bila je slična onoj u odraslih bolesnika nakon korekcije za razliku u tjelesnoj težini.
Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg.
Liječenje se mora započeti dozom od 2 mg (primjenom odgovarajućeg lijeka koji sadrži aripiprazol) tijekom prva 2 dana, a potom titrirati do 5 mg tijekom sljedeća 2 dana kako bi se postigla preporučena dnevna doza od 10 mg.
A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydroaripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.
Ispitivanje jednokratne doze u ispitanika s različitim stupnjevima ciroze jetre (Child-Pugh stadij A, B, i C) nije pokazalo da postoji značajan učinak oštećenja funkcije jetre na farmakokinetiku aripiprazola i dehidro-aripiprazola, ali ispitivanje je uključilo samo 3 bolesnika s cirozom jetre u stadiju C, što nije dovoljno da bi se mogli izvući zaključci o njihovom metaboličkom kapacitetu.
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Sandoz.
Također sprječavaju povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na liječenje lijekom Aripiprazol Sandoz.
87 cases had medical history of confounding risk factors such as balance disorders, loss of consciousness, syncope, somnolence, extrapyramidal disorder, femoral fracture, alcohol abuse, bundle branch block, osteoporosis, knee arthroplasty, spinal fusion surgery, road traffic accident, fall, transient ischemic attack, cerebrovascular accident, head injury and dementia with Lewy bodies and concomitant therapy with risperidone, quetiapine fumarate, clonazepam, Latuda, valium was a confounding factor in 172 cases.
U 87 slučajeva povijest bolesti je sadržavala zbunjujuće rizične čimbenike kao što su poremećaji ravnoteže, gubitak svijesti, sinkopa, somnolencija, ekstrapiramidni poremećaj, prijelom natkoljenične kosti, zloporaba alkohola, blok grane, osteoporoza, artroplastika koljena, operacija spinalne fuzije, prometna nesreća, pad, prolazna ishemijska ataka, cerebrovaskularni incident, ozljeda glave i demencija s Lewyjevim tjelešcima, dok je istodobna terapija risperidonom, kvetiapinfumaratom, klonazepamom, lijekom Latuda i diazepamom bila zbunjujući čimbenik u 172 slučaja.
Aripiprazole Sandoz is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Sandoz se ne preporučuje za primjenu u bolesnika sa shizofrenijom mlađih od 15 godina, zbog nedostatnih podataka o sigurnosti i djelotvornosti (vidjeti dijelove 4.8 i 5.1).
To allow the start of the treatment at a low dose you can use an alternative formulation (oral solution - liquid) more suitable than Aripiprazole Sandoz tablets.
Kako bi se liječenje moglo započeti nižom dozom, može se koristiti drugi farmaceutski oblik lijeka (oralna otopina - tekućina) koji je prikladniji od Aripiprazol
Warnings and precautions Talk to your doctor before taking Aripiprazole Sandoz.
Upozorenja i mjere opreza Obratite se svom liječniku prije nego što uzmete Aripiprazol
Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole.
Dismotilitet jednjaka i aspiracija povezani su s primjenom antipsihotika, uključujući aripiprazol.
Aripiprazole Sandoz contains the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Sandoz sadrži djelatnu tvar aripiprazol i pripadaju skupini lijekova koji se zovu antipsihotici.
Try to take Aripiprazole Sandoz at the same time each day.
Sandoz svaki dan u isto vrijeme.
Aripiprazole Sandoz is effective in a dose range of 10 to 30 mg/day.
Sandoz je učinkovit u rasponu doza od 10 do 30 mg/dan.
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5-HT1a and 5-HT2a receptors and moderate affinity for dopamine D4, serotonin 5-HT2c and 5-HT7, alpha-1 adrenergic and histamine H1 receptors.
Aripiprazol je in vitro pokazao visok afinitet vezanja za dopaminske D2 i D3, serotoninske 5HT1a i 5HT2a receptore i umjeren afinitet za dopaminske D4, serotoninske 5HT2c i 5HT7, alfa-1 adrenergičke i histaminske H1 receptore.
If you are taking Aripiprazole Sandoz, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding.
Sandoz, Vaš će liječnik razgovarati s Vama o tome trebate li dojiti uzimajući u obzir korist liječenja za Vas i korist dojenja za dijete.
It is likely that healthcare professionals would be able to diagnose oculogyric crisis as dystonia and therefore attribute this symptom to aripiprazole, however it is unlikely that patients would be able to link the eye movements to any of the side effects listed in the PIL.
Vjerojatno je da bi zdravstveni radnici mogli okulogirnu krizu dijagnosticirati kao distoniju te taj simptom pripisati aripiprazolu, međutim, nije vjerojatno da bi bolesnici mogli pokrete očiju povezati s nekom nuspojavom navedenom u uputi o lijeku.
Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls.
Aripiprazol može uzrokovati pospanost, pad krvnog tlaka pri ustajanju, vrtoglavicu i promjene u sposobnosti kretanja i ravnoteže, što može dovesti do padova.
UNIQUE IDENTIFIER - 2D BARCODE [Only Carton for bottle:]
17. JEDINSTVENI IDENTIFIKATOR - 2D BARKOD (Samo kutija za bocu:)
•high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine,
• povišenog šećera u krvi (karakteriziran simptomima poput pretjerane žeđi, obilnog mokrenja,
• acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,
• akutnu smetenost, napadaje (epilepsiju), komu, kombinaciju vrućice, ubrzanog disanja, znojenja,
Taking Aripiprazole Sandoz with some medicines may mean the doctor will need to change your dose of Aripiprazole Sandoz or the other medicines.
Sandoz s nekim lijekovima može značiti da će Vam liječnik morati promijeniti dozu lijeka Aripiprazol
Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Sandoz je indiciran za liječenje shizofrenije u odraslih i adolescenata u dobi od 15 i više godina.
Potential for aripiprazole to affect other medicinal products
Potencijal lijeka aripiprazol da utječe na druge lijekove
Aripiprazol may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls.
Aripiprazol može izazvati somnolenciju, posturalnu hipotenziju te motoričku i senzoričku nestabilnost, što može dovesti do padova.
The active substance is aripiprazole.
• Djelatna tvar je aripiprazol.
Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose.
Prevencija relapsa maničnih epizoda u bipolarnom poremećaju tipa I: za prevenciju relapsa maničnih epizoda u bolesnika koji već uzimaju aripiprazol u obliku monoterapije ili kombinirane terapije, nastavite s primjenom terapije u istoj dozi.
The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3% of patients treated with oral aripiprazole.
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima su akatizija i mučnina, od kojih se svaka javlja u više od 3 % bolesnika liječenih oralnim aripiprazolom.
Caution should be taken when treating patients at higher risk, and a lower starting dose should be considered (e.g elderly or debilitated patients) (see section 4.2).
Potreban je oprez pri liječenju bolesnika s povećanim rizikom te treba razmotriti primjenu niže početne doze (npr. stariji bolesnici ili bolesnici s narušenim zdravstvenim stanjem, vidjeti dio 4.2).
Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8%) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3%).
Shizofrenija: u dugotrajnom kontroliranom ispitivanju u trajanju od 52 tjedna, bolesnici liječeni aripiprazolom imali su nižu ukupnu incidenciju (25,8 %) EPS-a uključujući parkinsonizam, akatiziju, distoniju i diskineziju u usporedbi s onima liječenima haloperidolom (57,3 %).
HDPE bottle containing a silica gel desiccant and a polyester coil packed in cartons containing 100 tablets.
Boca od polietilena visoke gustoće (HDPE), koja sadrži silika gel kao sredstvo za sušenje i poliestersku vaticu pakirana u kutije koje sadrže 100 tableta.
The rate of death in aripiprazole-treated patients was 3.5% compared to 1.7% in the placebo group.
Stopa smrti u bolesnika liječenih aripiprazolom bila je 3,5 % u usporedbi s 1,7 % u onih koji su primali placebo.
In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
U kliničkim ispitivanjima, doze aripiprazola od 10 do 30 mg/dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin),
In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole.
U starijih osoba s demencijom prijavljeno je više smrtnih slučajeva za vrijeme liječenja aripiprazolom.
In three placebo-controlled trials (n=938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo.
U tri placebom kontrolirana ispitivanja aripiprazola u starijih bolesnika (n = 938; prosječna dob: 82,4 godine; raspon: 56-99 godina) s psihozom koja je bila povezana s Alzheimerovom bolešću, bolesnici liječeni aripiprazolom imali su povišen rizik od smrti u odnosu na bolesnike koji su primali placebo.
What Aripiprazole Sandoz tablets are and what they are used for What you need to know before you take Aripiprazole Sandoz tablets How to take Aripiprazole Sandoz tablets Possible side effects
Sandoz i za što se koristi Što morate znati prije nego počnete uzimati Aripiprazol Sandoz Kako uzimati Aripiprazol Sandoz Moguće nuspojave
Aripiprazole Sandozis used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Sandoz tablete koriste se za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied.
Slični učinci mogu se očekivati i kod istodobne primjene aripiprazola i drugih induktora CYP3A4 (kao što su rifampicin, rifabutin, fenitoin, fenobarbital, primidon, efavirenz, nevirapin i gospina trava) pa se stoga moraju provesti slična povećanja doza.
10 tablets 14 tablets 16 tablets 28 tablets 30 tablets 35 tablets 56 tablets 70 tablets
10 tableta 14 tableta 16 tableta 28 tableta 30 tableta 35 tableta 56 tableta 70 tableta
CZ-140 00 Praha 4 - Nusle
Na Pankráci 1724/129 CZ-140 00 Praha 4 - Nusle
In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Y-MRS and MADRS total scores ≤ 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46% decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65% decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression.
U placebom kontroliranom ispitivanju, koje je trajalo 52 tjedna, u bolesnika s trenutno prisutnim maničnim ili miješanim epizodama bipolarnog poremećaja tipa 1, koji su postigli kontinuiranu remisiju (Y-MRS i MADRS ukupni rezultat ≤ 12) s aripiprazolom (10 mg/dan do 30 mg/dan) kao adjuvantnom terapijom uz litij ili valproat tijekom 12 uzastopnih tjedana, adjuvantna terapija aripiprazolom pokazala je nadmoć u odnosu na placebo sa 46 %-tnim smanjenjem rizika (omjer hazarda je 0,54) u prevenciji ponavljanja bipolarnog poremećaja i sa 65 %-tnim smanjenjem rizika (omjer hazarda je 0,35) u prevenciji ponavljanja maničnog poremećaja u odnosu na adjuvantnu terapiju placebom, ali nije uspjela pokazati nadmoć u odnosu na placebo u prevenciji ponavljanja depresije.